NewsEvents

Your Yourlocation: Home > Inhalation of tiotropium bromide(136310-93-5) and formoterol in the treatment of COPD

To observe the effect and safety of inhalation of tiotropium bromide(136310-93-5), formoterol and co-inhalation in the treatment of chronic obstructive pulmonary disease.

Methods: Using cross design, self control, 76 patients with COPD were followed by three consecutive 6 weeks test period, a period: daily 9 am inhalation tiotropium bromide(136310-93-5) 18μg; Phase II: daily 9 am, 9 pm each inhalation of formoterol 9μg; three: daily 9am inhalation tiotropium bromide 18μg, and inhalation(P <0.05). There was no significant difference between the two groups(P <0.05). There was no significant difference between the two groups(P <0.05). There was no significant difference between the control group and the control group(P <0.001), and the change of FVC was similar to that of FEV1. The combination therapy was effective in reducing the daily symptom effect(P <0.001), and the difference between the two groups was significantly higher than that of the control group(P <0.001) and the effect of inhaled tiotropium was significantly stronger than that of formoterol, and the nighttime control ability was comparable to that of formoterol, the combination was better than monotherapy.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved